YENO Evolution GmbH
coming soon
YENO Evolution is a research and development company in the field of non-molecular cell regulation, applied epigenetics and regulatory medicine. The research is based on the use of medical devices and technologies such as the YENO Quantum ONE developed by YENO.
For 22 years, YENO has focused on research and development for non-molecular cell stimulation (biophysics and epigenetics). The GENOS procedure, patented in Europe and the USA, provides direct cell nucleus access with regulation of epigenetic key positions for the first time. The GENOS procedure arose from the cross know-how of 22 years of experience in medical cause diagnostic, epigenetic, biomedicine, pharmacology and -kinetic, biophysics, space medicine and process technology and is based on applied elements that have been selectively and purposefully harmonized with each other, with the help of combined specialist expertise.
This unique combination not only represents an innovation in application, but is also a trailblazing impulse on the current healthcare market.
YENO is a leader in the field of applied epigenetics, which is due to the use of the body's own (biophysically stimulated) signal transduction molecule RM31, which acts as a pure signal. All medications developed from the research results (GENOS products) represent personalized epigenetic medicine with direct intranuclear access and epigenetic regulation of important key positions.
Currently, 82 drugs are available that have been approved according to §21 AMG (German medical act) and represent a new generation of medicine. The effect of cell regulation is based on the use of signal transduction and cell reprogramming and has been demonstrated in both in vitro and in vivo studies. The effect of the signal transduction molecule RM31 on HL60 cells (leukemia cells) with a 99.5% inhibition of telomerase activity in just 72 hours was published in March 2022.
